NewAmsterdam Pharma Company N.V.
NASDAQ: NAMS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Harvey Davidson Facp.
- Employees
- 68
- Headquarters
- Naarden, United States
- IPO year
- 2021
- Market cap
- $3.5B
- Website
- https://www.newamsterdampharma.com
Loading NAMS…
Loading profile data…Frequently asked questions about NAMS
What does NewAmsterdam Pharma Company N.V. (NAMS) do?
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CET...
Where does NAMS trade?
NewAmsterdam Pharma Company N.V. (NAMS) trades on the NASDAQ Capital Market.
What sector is NAMS in?
NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NewAmsterdam Pharma Company N.V.?
Michael Harvey Davidson Facp. is the chief executive officer of NewAmsterdam Pharma Company N.V. (NAMS).
Where is NewAmsterdam Pharma Company N.V. headquartered?
NewAmsterdam Pharma Company N.V. is headquartered in United States.
Does NAMS pay a dividend?
NewAmsterdam Pharma Company N.V. (NAMS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NAMS go public?
NewAmsterdam Pharma Company N.V. (NAMS) completed its initial public offering in 2021.